<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874455</url>
  </required_header>
  <id_info>
    <org_study_id>EZH-701</org_study_id>
    <nct_id>NCT03874455</nct_id>
  </id_info>
  <brief_title>Tazemetostat Expanded Access Program for Adults With Solid Tumors</brief_title>
  <official_title>Tazemetostat Expanded Access Program for Adults With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epizyme, Inc.</source>
  <brief_summary>
    <textblock>
      Patients with following conditions are eligible to enroll in the EAP:&#xD;
&#xD;
        -  Epithelioid Sarcoma (ES) **ex-US Only**&#xD;
&#xD;
        -  Spindle cell sarcoma&#xD;
&#xD;
        -  Sinonasal carcinoma&#xD;
&#xD;
        -  Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT)&#xD;
&#xD;
        -  Thoracic sarcoma&#xD;
&#xD;
        -  Poorly differentiated chordoma&#xD;
&#xD;
      These conditions must be serious or life-threatening at the time of enrollment and&#xD;
      appropriate, comparable, or satisfactory alternative treatments must have been tried without&#xD;
      clinical success. Patients with conditions not listed above are not eligible for the&#xD;
      tazemetostat EAP&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Epithelioid Sarcoma (Ex-US Only)</condition>
  <condition>Spindle Cell Sarcoma</condition>
  <condition>Sinonasal Carcinoma</condition>
  <condition>Small Cell Carcinoma of the Ovary Hypercalcemic Type</condition>
  <condition>Thoracic Sarcoma</condition>
  <condition>Poorly Differentiated Chordoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene</description>
    <other_name>EPZ-6438</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age (at the time of consent): &gt;18 years of age.&#xD;
&#xD;
          2. They are unable to participate in tazemetostat clinical trials for their condition.&#xD;
&#xD;
          3. Can provide signed written informed consent.&#xD;
&#xD;
          4. Documented loss of INI1 or SMARCA4 confirmed by IHC, or molecular confirmation of&#xD;
             tumor bi-allelic INI1 or SMARCA4 loss or mutation when INI1 or SMARCA4 IHC is&#xD;
             equivocal or unavailable.&#xD;
&#xD;
          5. Female patients of childbearing potential should:&#xD;
&#xD;
               -  Agree to practice one highly effective method of contraception and one additional&#xD;
                  effective (barrier, for example condom or diaphragm with spermicide) method at&#xD;
                  the same time, from the time of providing voluntary written informed consent&#xD;
                  through (30 days or 5 half-lives, whichever is longer) after the last dose of&#xD;
                  tazemetostat, and&#xD;
&#xD;
               -  Have a negative beta-human chorionic gonadotropin (β-hCG) pregnancy test at time&#xD;
                  of screening and within 14 days prior to planned first dose of tazemetostat&#xD;
                  (urine or serum test is acceptable however, positive urine tests must be&#xD;
                  confirmed with serum testing), and&#xD;
&#xD;
               -  Agree to use effective contraception from start of screening until 30 days&#xD;
                  following the last dose of tazemetostat and have a male partner who uses a&#xD;
                  condom, or&#xD;
&#xD;
               -  Practice true abstinence, (when this is in line with the preferred and usual&#xD;
                  lifestyle of the patient or&#xD;
&#xD;
               -  Have a male partner who is vasectomized.&#xD;
&#xD;
          6. Male patients with a female partner of childbearing potential should:&#xD;
&#xD;
               -  Be vasectomized, or&#xD;
&#xD;
               -  Agree to use condoms from first dose of tazemetostat until 30 days following the&#xD;
                  last dose of tazemetostat, or&#xD;
&#xD;
               -  Have a female partner who is NOT of childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet&#xD;
             and all foods that contain those fruits from time of enrollment to while on the EAP.&#xD;
&#xD;
          2. Is currently taking any prohibited medication(s) as described in section 6.3.&#xD;
&#xD;
          3. Has known hypersensitivity to any of the components of tazemetostat or other&#xD;
             inhibitor(s) of EZH2.&#xD;
&#xD;
          4. Has thrombocytopenia, neutropenia, or anemia of grade ≥3 (per CTCAE 4.03 criteria)&#xD;
             within the past month, or any prior history of myeloid malignancies, including&#xD;
             myelodysplastic syndrome (MDS).&#xD;
&#xD;
          5. Is known to have any abnormalities associated with MDS (e.g. del 5q, chr 7 abn) and&#xD;
             MPN (e.g. JAK2 V617F) observed in cytogenetic testing and DNA sequencing.&#xD;
&#xD;
          6. Has a prior history of T-LBL/T-ALL.&#xD;
&#xD;
          7. For female patients of childbearing potential: Is pregnant or nursing.&#xD;
&#xD;
          8. For male patients: Is unwilling to adhere to contraception criteria from time of&#xD;
             enrollment in study to at least 30 days after last dose of tazemetostat.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Chelsea Mencio</last_name>
    <phone>855-500-1011</phone>
    <email>Cmencio@epizyme.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Chordoma</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

